MartikainenT.A., TeppoA.M., Grönhagen-RiskaC., EkstrandA.Glucose-free dialysis solutions: Inductors of inflammation or preservers of peritoneal membrane?Perit Dial Int2005; 25: 453–60.
2.
PosthumaN., ter WeeP.M., DonkerA.J., OeP.L., PeersE.M., VerbrughH.A.Assessment of the effectiveness, safety, and biocompatibility of icodextrin in automated peritoneal dialysis. The Dextrin in APD in Amsterdam (DIANA) Group.Perit Dial Int2000; 20(Suppl 2): S106–13.
3.
DaviesS.J., BrownE.A., FrandsenN.E., RodriguesA.S., Rodriguez-CarmonaA., VychytilA.Longitudinal membrane function in functionally anuric patients treated with APD: Data from EAPOS on the effects of glucose and icodextrin prescription.Kidney Int2005; 67: 1609–15.
4.
PaniaguaR., AmatoD., VoneshE., Correa-RotterR., RamosA., MoranJ.Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trial.J Am Soc Nephrol2002; 13: 1307–20.
5.
le PooleC.Y., WeltenA.G., WeijmerM.C., ValentijnR.M., van IttersumF.J., ter WeeP.M.Initiating CAPD with a regimen low in glucose and glucose degradation products, with icodextrin and amino acids (NEPP) is safe and efficacious.Perit Dial Int2005; 25(Suppl 3): S64–8.
6.
GillerotG., GoffinE., MichelC., EvenepoelP., Van BiesenW., TintillierM.Genetic and clinical factors influence the baseline permeability of the peritoneal membrane.Kidney Int2005; 67: 2477–85.
7.
JonesS.A., HoriuchiS., TopleyN., YamamotoN., FullerG.M.The soluble interleukin-6 receptor mechanisms of production and implications in disease.FASEB J2001; 15: 43–8.
8.
LiF.K., ChanL.Y., WooJ.C., HoS.K., LoW.K., LaiK.N.A 3-year, prospective, randomized, controlled study on amino acid dialysate in patients on CAPD.Am J Kidney Dis2003; 42: 173–83.
